Header5

The simple corporate scheme behind massive US Brand Drug Prices

My 7-year whistleblower effort
"People Before Profits"

Whistleblower Cases: Worst Offenders

“Old” Blockbuster U.S Brand Drugs: Massive Price Increases, Declining Use

Worst Offender Profiles:

1) Vast increases in REPORTED pharma company U.S. sales for an "old" blockbuster drug since Medicare Part D began

 2) ALL U.S. brand drug sales growth is driven by massive 5-to-10-fold U.S. price increases…

 3) While clinical use of the U.S. brand drug by physicians and patients is SHARPLY DECLINING due to severe competition 

THIS CANNOT HAPPEN IN A LEGITIMATE U.S. PHARMACEUTICAL MARKET!!!


U.S. Multiple Sclerosis (MS) Market:

  • Uniform massive U.S. brand price increases in the MS category from $15,000 to $100,000 per patient/year since Medicare Part D began
  • Despite severe competition and many new similar MS drugs reaching the U.S. market
  • MASSIVE PRICE INCREASES FOR "OLD" U.S. MS BRAND DRUGS DESPITE PLUMMETING USE AND MARKET SHARE
  • Severe pricing harm ONLY for Americans; competition prevented MS price increases outside the U.S.

Biogen’s Avonex (MS, on U.S. market since 1996)

  • 2005 Reported U.S. Sales: $939 million
  • 2017 Reported U.S. Sales: $1.9 billion
  • U.S. Clinical Use/Prescriptions DOWN 60-70% since 2005
  • 2017 U.S. Sales WITHOUT Price Increases: $322 million
  • 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker” Price: $100,000/patient/year
  • Cumulative harm since start of Part D: $12.5+ billion

Teva’s Copaxone (MS, on U.S. market since 1996)

  • 2005 Reported U.S. Sales: $782 million
  • 2017 Reported U.S. Sales: $3.0 billion
  • U.S. Clinical Use/Prescriptions DOWN -40-50% since 2005
  • 2017 U.S. Sales WITHOUT Price Increases: $530 million
  • 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker” Price: $100,000/patient/year
  • Cumulative harm since start of Part D: $20 billion

U.S. Insulin Market 

  • Uniform massive 5-10-fold U.S. insulin price increases in the decade-plus since Medicare Part D began
  • Despite severe competition among numerous similar products
    • Many insulins on the U.S. market for decades
  • Severe U.S. patient and family harm
    • Diabetes is the highest spending U.S. brand drug category
    • Rising U.S. deaths from unaffordable insulin
    • Diabetics traveling to abroad for cheaper black market insulin

Sanofi's Lantus (long-acting insulin, on U.S. market since 2000)

Eli Lilly’s Humulin (on U.S. market since 1982)


U.S. Rheumatoid Arthritis/Autoimmune Market 

  • Uniform massive 5-10-fold U.S. price increases in the decade-plus since Medicare Part D began
    • from about $15,000 patient/year before Part D to the $75,000 patient/year range now
  • Despite rising competition from numerous similar new drugs reaching the U.S market

Amgen’s Enbrel (on U.S. market since 1997)

  • 2005 Reported U.S. Sales: $2.47 billion
  • 2017 Reported U.S. Sales: $5.2 billion
  • U.S. Clinical Use/Prescriptions DOWN -25% since 2005
  • 2017 U.S. Sales WITHOUT Price Increases: $1.9 billion
  • 2005 U.S. “List”/“Sticker”: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker”: $75,000/patient/year
  • Cumulative harm since start of Part D: $19.1+ billion

Abbvie’s Humira (on U.S. market since 2003)

  • 2005 Reported U.S. Sales: $560 million
  • 2017 Reported U.S. Sales: $12.4 billion
  • 2017 U.S. Sales WITHOUT Price Increases: $3.8 billion
  • 2005 U.S. “List”/“Sticker”: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker”: $75,000/patient/year
  • Cumulative harm since start of Part D: $32.3+ billion

U.S. Cancer Market: Novartis' Gleevec (Leukemia, on U.S market since 2001) 

  • Massive 5-Fold U.S. price after Part D began
    • Majority of Gleevec use in Medicare Part D prior
    • Early 2016 U.S. patent expiration

Other Major U.S. Brands 

Pfizer’s Lyrica (seizures/diabetics, on U.S. market since 2004)

  • 2005 Reported U.S. Sales: $717 million
  • 2017 Reported U.S. Sales: $3.5 billion
  • 2017 U.S. Sales WITHOUT Price Increases: $1.16 billion
  • Cumulative harm since start of Part D: $10.0+ billion

Other major U.S. Pfizer brands:

 

 

 

Receive the Latest News

Your email is 100% safe.
Your privacy will be respected.
!
!
Something went wrong. Please check your entries and try again.
Scroll to Top